首页> 外文期刊>Open Journal of Medical Microbiology >High Prevalence of Multidrug Resistant &i&Klebsiella&/i& Species Isolated from the Yaounde University Teaching Hospital, Cameroon
【24h】

High Prevalence of Multidrug Resistant &i&Klebsiella&/i& Species Isolated from the Yaounde University Teaching Hospital, Cameroon

机译:多药抗性患病率较高; LT; I& klebsiella& / i& 喀麦隆大学教学医院孤立的物种

获取原文
       

摘要

Background and Purpose: Klebsiella species are amongst the most common causes of a variety of community-acquired and hospital-acquired infections (HAI), characterized by high morbidity and mortality rates. Most infections caused by Klebsiella species are usually treated using antibiotics. The aim of this study was to determine the antimicrobial resistance profile of Klebsiella species isolated from in-patients and out-patients at the Yaounde University Teaching Hospital. The data generated will go a long way to improve on the choice of an adequate empiric antibiotic treatment for infections caused by Klebsiella species. Methodology: A cross - sectional descriptive study was carried out over a period of 6 months, spanning from February 2019 to July 2019 with a sample size of 37 isolates, obtained from 6 different clinical specimens. Identification of isolates was done using API 20E identification system (Bio merieux SA, Lyon, France). Susceptibility to antibiotics was tested as de scribed by Kirby-Bauer in 1956. Inhibition diameters were interpreted according to recommendations from the European Committee on Antimicrobial Suscepti bility Testing (EUCAST, 2019). Results and Conclusion: Among the 37 Klebsiella isolates identified, Klebsiella pneumoniae was the most prevalent species isolated with a percentage of 54.1%, followed by Klebsiella rhinoscleromatis 18.9%, Klebsiella ozaenae 16.2% and Klebsiella oxytoca , 10.8%. The resistance pattern of Klebsiella to amoxicillin, amoxicillin/clavulanate, tircacillin, tircacillin + clavulanic acid, piperacillin, piperacillin + tazobactam, cefalotin, cefuroxim, ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, meropenem, aztreonam, amikacin, gentamicin, tobramycin, trimethoprim/ sulfamethoxazole, nalidixic acid, pipemidic acid, norfloxacin, ciprofloxacin, levofloxacin, ofloxacin, and moxifoxacin was as follows; 100%, 86.5%, 97.3%, 83.6%, 86.5%, 16.2%, 86.5%, 83.8%, 78.4%, 32.4%, 78.4%, 76.7%, 2.7%, 2.7%, 76.7%, 13.5%, 75.7%, 73.0%, 91.9%, 51.4%, 48.6%, 64.9%, 48.6%, 48.6%, 73.0% and 62.2% respectively. Multidrug resistance was observed in 94.6% of the Klebsiella isolates. Conclusion: This study shows that the level of multidrug resistance is high. The isolates expressed good sensitivity to carbapenems, piperacillin + tazobactam, amikacin and high resistance to all other antimicrobials tested. Therefore, antimicrobial susceptibility test ing prior to prescriptions should be encouraged and sensitization of the population about consequences of inappropriate antibiotic treatment and auto medication should be enforced as a mean s to curb antimicrobial resistance .
机译:背景和目的: Klebsiella物种是各种社区获得的和医院收购的最常见的原因之一,其特征在于高发病率和死亡率。由 klebsiella物种引起的大多数感染通常使用抗生素治疗。该研究的目的是确定雅温得大学教学医院中患者中分离的患者和OUT患者的抗菌性抗菌性曲线。产生的数据将是改善适当验证抗生素治疗的漫长方法,以对克鲁布尔贝拉物种引起的感染。 方法:在2019年2月至2019年2月的跨越6个月内进行横截面描述研究,其样本量为37分离物,从6种不同的临床标本获得。使用API​​ 20E识别系统(Bio Merieux SA,Lyon,France)进行分离物的鉴定。 1956年被Kirby-Bauer划出的DE抗生素的易感性。抑制直径根据欧洲抗菌基因敏感性测试检测(EUCAST,2019)的建议来解释抑制直径。 结果和结论:鉴定的37℃, Klebsiella肺炎是最普遍的物种,其百分比为54.1%,其次是 klebsiella rhinoscleromatis 18.9%, klebsiella ozaenae 16.2%和 Klebsiella oxytoca,10.8%。 抗血糖蛋白,阿莫西林/克拉维拉酸,滴毛蛋白,滴毛蛋白+克拉维兰酸,哌啶素,哌啶素+ Tazobactam,Cefalotin,Cefuroxim,头孢唑胺,头孢噻肟,头孢菌蛋白,头孢唑胺,伊皮脂,梅洛尼姆,阿兹特瓜兰,阿米卡星,庆大霉素, Tabramycin,Trimethokim /磺胺甲恶唑,萘啶酸,哌啶酸,诺氟沙星,环丙沙星,氟甲酰辛,氧氟沙星和咪昔芬加辛,如下; 100%,86.5%,97.3%,83.6%,86.5%,16.2%,86.5%,83.8%,78.4%,32.4%,78.4%,76.7%,2.7%,2.7%,76.7%,13.5%,75.7% 73.0%,91.9%,51.4%,48.6%,64.9%,48.6%,48.6%,73.0%和62.2%。在94.6%的 Klebsiella隔离物中观察到多药抗性。 结论:本研究表明,多药耐药程度高。该分离物对CarbapeNems,Piperacillin + Tazobactam,Amikacin和高抗性对所有其他抗微生物的抗性表达了良好的敏感性。因此,应促进处置前的抗微生物易感性试验,并促进和敏化患有不恰当的抗生素治疗的后果和自动用药的敏化,作为抑制抗微生物抗性的平均值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号